Search Results

You are looking at 91 - 100 of 177 items for :

  • "cetuximab" x
  • All content x
Clear All
Full access

Harold J. Burstein

cetuximab after prior epidermal growth factor receptor (EGFR) inhibitor treatment. Despite the NCCN Guidelines admonitions, many patients received non-recommended treatments (10% received bevacizumab, 16% inhibitors, and 49% capecitabine). Costs for these

Full access

Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack

comparing lapatinib and placebo in advanced bladder cancer is underway; this study will be limited to patients characterized as 2+ or 3+ by immunohistochemistry ( identifier: NCT00949455). Cetuximab, a monoclonal antibody directed at

Full access

Helena A. Yu and Gregory J. Riely

/II study of erlotinib and cetuximab did not show any significant activity in patients with acquired resistance to erlotinib. 45 A recently completed study evaluated the combination of afatinib and cetuximab in patients with advanced NSCLC whose disease

Full access

Bruce D. Minsky, Claus Rödel, and Vincenzo Valentini

benefit of adding targeted biologic agents, such as bevacizumab and cetuximab, is being tested. Initial phase I/II trials of bevacizumab plus preoperative 5-FU or capecitabine-based chemoradiation revealed pCR rates of 18% to 24%. 17 , 18 However, more

Full access

David Y. Oh, Alan P. Venook, and Lawrence Fong

responses. 26 Antibodies as Immunotherapy Cetuximab is a chimeric IgG1 monoclonal antibody that competitively binds to the extracellular domain of the EGFR, preventing dimerization, tyrosine kinase phosphorylation, and activation. This antibody has

Full access

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Janis O’Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, Stephen C. Yang, Miranda Hughes, and Kristina M. Gregory

is a small molecule inhibitor of EGFR; crizotinib is a small molecule inhibitor that targets ALK and MET. Cetuximab is a monoclonal antibody that targets EGFR. In 2006, the FDA approved bevacizumab for patients with unresectable, locally advanced

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass

.gov identifier: NCT00093379). Preliminary results from this trial seem promising. 53 Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor, whose anti-tumor activity depends on the presence of wild-type KRAS . 54 Because KRAS mutations appear to

Full access

Potjana Jitawatanarat, Arpita Desai, Pradeep Sharda, Hong Liu, Maureen Ross, Francisco J. Hernandez-llizaliturri, Philip L. McCarthy, and George L. Chen

receptors FcγR2a and FcγR3a, which result in stronger binding to the IgG1 Fc region, have also been shown to enhance antibody-dependent cell-mediated cytotoxicity for many antibodies in clinical use, such as rituximab, cetuximab, and trastuzumab. 17 – 19

Full access

Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger

. Conversely, the incidence of other adverse events, such as gastrointestinal perforation, venous thromboembolic events, hypertension, and bleeding, did not increase with increasing age in these analyses. 68 , 70 , 71 , 74 Cetuximab/Panitumumab The data

Full access

Sharon Spencer

reevaluations. Responding patients were then treated with weekly cetuximab and reduced-dosed RT at 54 Gy. Patient outcomes were encouraging, as significantly fewer patients treated with the 54 Gy of RT experienced difficulty swallowing solids. There is promise